Form 990 for tax year 2024

Totals

Total revenue

$159,100,585

Total expenses

$143,670,256

Contributions and grants received

$7,681,674

Grants paid

$5,363,509

Program service revenue

$137,635,933

Investment income

$9,082,224

Other revenue

$4,700,754

Total assets, end of year

$321,716,381

Total liabilities, end of year

$111,219,799

Net assets or fund balances, end of year

$210,496,582

Program services expenses (Part IX)

$109,621,340

Management and general expenses

$34,048,916

Fundraising expenses

$0

Program service expenses (Part III)

$109,621,340

Program services were 76.3% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Mission and programs · 2024

• SEE SCHEDULE O:SCIENTIFIC & MEDICAL EDUCATION:ASCO'S MEETING PORTFOLIO DELIVERS, TO ASCO'S CORE AUDIENCE OF HEALTH PROFESSIONALS, THE SCIENCE AND EDUCATION CRITICAL TO IMPROVING PATIENT CARE AND CLINICAL PRACTICE BY HOSTING CONFERENCES THAT BRING TOGETHER FACULTY AND PRACTITIONERS BOTH IN-PERSON AND ONLINE. IN 2024, ASCO'S PREMIER ANNUAL MEETING, THROUGH OVER 200 SESSIONS, REACHED AN AUDIENCE OF 36,400 PROFESSIONALS, INCLUDING OVER 14,400 PROFESSIONALS FROM 140 NON-US COUNTRIES, BOTH IN-PERSON AND ONLINE. THROUGH ASCO'S ADDITIONAL MEETINGS, THE ASCO GASTROINTESTINAL CANCERS SYMPOSIUM, THE ASCO GENITOURINARY CANCERS SYMPOSIUM, THE ASCO QUALITY CARE SYMPOSIUM, ASCO BREAKTHROUGH, AND THE BEST OF ASCO MEETING, A FURTHER 10,400 PROFESSIONALS, OVER 4,100 OF WHOM WERE OUTSIDE THE UNITED STATES, BENEFITED FROM THE EDUCATION, SCIENCE, AND NETWORKING THAT ASCO PROVIDED.

  Expenses $70,800,952 · Grants $5,283,009 · Revenue $109,069,704

• SEE SCHEDULE O:RESEARCH INITIATIVES - TAPUR/CENTRA:ASCO'S CENTER FOR RESEARCH AND ANALYTICS "(CENTRA)" LEADS ASCO'S EFFORTS IN RESEARCH AND RELATED TO CLINICAL CANCER RESEARCH. MAJOR PROGRAMS AND PROJECTS INCLUDE: (1) THE TARGETED AGENT AND PROFILING UTILIZATION REGISTRY (TAPUR) STUDY, WHICH IS A PRECISION MEDICINE BASKET TRIAL THAT INVESTIGATES THE EFFICACY OF MORE THAN 15 DIFFERENT ANTI-CANCER TARGETED AGENTS IN PATIENTS WITH ADVANCED CANCERS AND HAS ENROLLED NEARLY 3,000 PATIENTS SINCE IT OPENED IN 2016. TAPUR CONTINUES TO PUBLISH TRIAL RESULTS IN PEER-REVIEWED CLINICAL CANCER RESEARCH JOURNALS AND PRESENT RESULTS AT CLINICAL CANCER RESEARCH CONFERENCES; (2) ASCO'S MEMBER RESEARCH SURVEY POOL, WHICH FACILITATES RESEARCH OF CANCER CARE PROVIDERS BY DISSEMINATING SURVEYS FROM MERITORIOUS SURVEY RESEARCH PROJECTS TO ASCO MEMBERS WHO HAVE AGREED TO BE A PART OF THE SURVEY POOL; (3) THE STATE OF CANCER CARE IN AMERICA PROGRAM, WHICH ASSESSES AND REPORTS ON THE STATE OF AND CHANGES IN CANCER CARE IN THE US; (4) ASCO'S WORK IN IMPROVING ACCESS TO CLINICAL TRIALS THROUGH TRAINING FOR SITES; AND (5) A PATIENT-CENTERED CLINICAL TRIAL, THE CDK4/6 INHIBITOR DOSING STUDY, WHICH OPENED TO ENROLLMENT IN DECEMBER 2024 AND EVALUATES STANDARD VS. TITRATED DOSING APPROACHES FOR PATIENTS AGE 65 AND OLDER WITH HR+/HER2- METASTATIC BREAST CANCER. CENTRA ALSO SUPPORTS WORKSHOPS, MEETINGS, AND RESEARCH PROJECTS WITH OTHER STAKEHOLDERS IN CANCER RESEARCH, INCLUDING THE NCI, THE FDA'S ONCOLOGY CENTER FOR EXCELLENCE, AND OTHER NON-PROFIT GROUPS, SUCH AS THE FRIENDS OF CANCER RESEARCH.

  Expenses $9,374,885 · Revenue $4,963,700

• SEE SCHEDULE O:QUALITY OF CARE INITIATIVES:QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI) IS A QUALITY SELF-ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES. QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICES TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. PRACTICES PARTICIPATE ANNUALLY AND OVER 263 PRATICES PARTICAPTED IN 2024. QUALITY TRAINING PROGRAM. ASCO'S QUALITY TRAINING PROGRAM IS DESIGNED TO EDUCATE AND TRAIN HEMATOLGY-ONOCOLOGY PRACTICE TEAMS ON THE TECHNIQUES OF CLINICAL CARE AND OPERATIONAL PERFORMANCE QUALITY IMPROVEMENT. 290 ONCOLOGY PROFESSIONALS RECEIVED TRAINING IN 2024.GUIDELINES. ASCO'S GUIDELINES PROGRAM ENGAGES WITH MORE THAN 1,000 ASCO MEMBER VOLUNTEERS, ON A YEARLY BASIS, TO DEVELOP EXPERT RECOMMENDATIONS AND STANDARDS DESIGNED TO PROMOTE CONSISTENT, SAFE DELIVERY OF HIGH-QUALITY CANCER CARE WORLDWIDE. CLINICAL CONTENT IS DISSEMINATED USING PUBLISHED ARTICLES, RECOMMENDATION TABLES, ALGORITHMS, PODCASTS, VISUAL ABSTRACTS, AND OTHER RESOURCES ACCESSIBLE THROUGH ASCO JOURNALS, THE ASCO WEBSITE, AND THE ASCO GUIDELINES APP. GUIDELINES ARE AMONG THE MOST READ ARTICLES IN THE JOURNAL OF CLINICAL ONCOLOGY (JCO), WITH OVER 1.1 MILLION DOWNLOADS AND 503 CITATIONS IN 2024. ASCO PUBLISHES BETWEEN 25 AND 30 NEW OR UPDATED GUIDELINES EACH YEAR, WITH A GROWING LIBRARY OF GUIDELINE SUMMARIES THAT HAVE BEEN TRANSLATED INTO SPANISH. A TOTAL OF 39 GUIDELINE PRODUCTS WERE PUBLISHED IN THE JCO FAMILY OF JOURNALS IN 2024, INCLUDING SEVERAL RAPID RECOMMENDATIONS AND MULTIPLE ITERATIONS OF ASCO'S COMPREHENSIVE LIVING GUIDELINE THAT ADDRESSES THE CARE OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER.

  Expenses $9,146,436 · Grants $8,000 · Revenue $1,452,853

• POLICY:IN COLLABORATION WITH VOLUNTEER EXPERTS, ASCO WORKS TO ADDRESS A WIDE RANGE OF POLICY ISSUES THAT IMPACT THE CANCER CARE DELIVERY SYSTEM AND PEOPLE WITH CANCER. POLICY IS CONVEYED IN FORMAL STATEMENTS PUBLISHED IN ASCO JOURNALS, AND IN PUBLIC FACING COMMUNICATIONS CHANNELS. AREAS OF FOCUS INCLUDE QUALITY AND ACCESS TO CARE, INSURANCE ISSUES, COST, PREVENTION, SURVIVORSHIP, REIMBURSEMENT, AND SUPPORT FOR CLINICAL CANCER RESEARCH. IN 2024, ASCO CONTINUED TO DRAW PUBLIC ATTENTION TO THE PERSISTENT CRISIS OF DRUG SHORTAGES, THE ONGOING AND WORSENING HARMS RELATED TO AGGRESSIVE UTILIZATION MANAGEMENT PRACTICES, THE NEED TO SUSTAIN ACCESS TO EVIDENCE BASED CANCER CARE, THE NEED TO BALANCE BENEFITS/HARMS ASSOCIATED WITH USE OF ARTIFICIAL INTELLIGENCE IN CANCER CARE, AND THE IMPORTANCE OF TELEMEDICINE AS A COMPONENT OF HEALTH CARE DELIVERY.CENTER FOR GLOBAL IMPACT (CGI):ASCO'S INTERNATIONAL AFFAIRS DEPARTMENT HAS TRANSITIONED TO THE CENTER FOR GLOBAL IMPACT (CGI). CGI PARTNERS ACROSS ASCO AND ONCOLOGY COMMUNITIES WORLDWIDE TO INTEGRATE GLOBAL PERSPECTIVES INTO ASCO STRATEGIES AND OPERATIONS, AND TO CATALYZE AND ADVANCE ASCO'S GLOBAL IMPACT GOALS AS DIRECTED BY THE SOCIETY'S MISSION, VISION, AND STRATEGIC PLANS. CGI SERVES AS A RESOURCE ACROSS ASCO FOR GLOBAL ISSUES RELEVANT TO ASCO, WITH A PARTICULAR EMPHASIS ON VOLUNTEER ENGAGEMENT, DIPLOMACY, STRATEGIC PLANNING, PROGRAM DELIVERY, AND GLOBAL OPERATIONS. EXAMPLES OF OPERATIONS ARE AS FOLLOWS:- JOINT SESSIONS- INTERNATIONAL CANCER CORPS- INTERNATIONAL COURSES- INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD (IDEA)SCIENTIFIC PUBLICATIONS:ASCO PRODUCES A NUMBER OF PROFESSIONAL PUBLICATIONS AND GENERAL PUBLICATIONS FOCUSED ON CLINICAL ONCOLOGY. ASCO PUBLISHES HIGH-QUALITY, PEER-REVIEWED SCIENTIFIC PAPERS IN ITS JOURNALS: - JOURNAL OF CLINICAL ONCOLOGY (JCO)- JCO ONCOLOGY PRACTICE (JCO OP)- JCO GLOBAL ONCOLOGY (JCO GO)- JCO CLINICAL CANCER INFORMATICS (JCO CCI)- JCO PRECISION ONCOLOGY (JCO PO)- JCO ONCOLOGY ADVANCES (JCO OA)- ASCO DAILY NEWSASCO ALSO PROVIDES CONTENT AND DISTRIBUTION LISTS FOR TRADE PUBLICATIONS. WHILE NOT OWNED OR PUBLISHED BY ASCO, THE PUBLICATIONS COVER NEWS AND INFORMATION OF INTEREST TO THE PROFESSIONAL ONCOLOGY COMMUNITY.EDUCATION AND PROFESSIONAL DEVELOPMENT:IN 2024, ASCO LAUNCHED THE INAUGURAL LEADERSHIP DEVELOPMENT PROGRAM (LDP): LATIN AMERICA CLASS OF 12, CREATING A NETWORK OF PHYSICIAN LEADERS TO ADVANCE CANCER CARE. IN 2024, ASCO HAD RECORD VIRTUAL MENTORING PROGRAM PARTICIPATION (68% INCREASE), RESULTING IN THE CREATION OF A TECHNOLOGICAL SOLUTION TO MEET THE DEMAND. THE IN-TRAINING EXAM FOR ONCOLOGY FELLOWS HAD RECORD PARTICIPATION WITH 2333 TRAINEES FROM 20 COUNTRIES ACROSS THE GLOBE PARTICIPATING. ALL PROGRAMS SERVE THE PURPOSE OF BUILDING THE WORKFORCE.

  Expenses $20,299,067 · Grants $72,500 · Revenue $22,149,676

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

• CONQUER CANCER FOUNDATION OF ASCO

  $3,770,000

  CONTRIBUTION

• UNIVERSITY OF PENNSYLVANIA

  $195,000

  CANCER RESEARCH & EDUCATION

• UNIVERSITY OF CALIFORNIA SAN FRANCISCO

  $169,872

  CONTRIBUTION

• CINCINNATI CANCER FOUNDATION INC

  $152,500

  CONTRIBUTION

• YALE UNIVERSITY

  $95,250

  CONTRIBUTION

• BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

  $84,872

  CLINICAL INVESTIGATOR LEADERSHIP AWARD

• JOHNS HOPKINS UNIVERSITY

  $84,872

  CONTRIBUTION

• MAYO CLINIC JACKSONVILLE

  $84,872

  CONTRIBUTION

• MEMORIAL SLOAN KETTERING CANCER CENTER

  $84,872

  CONTRIBUTION

• UNIVERSITY OF FLORIDA

  $84,872

  CONTRIBUTION

The 10 largest by cash amount. The API serves every itemized grant.

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

• CONQUER CANCER FOUNDATION OF ASCO

  501(C)(3) · GRANTMAKING · VA · controlled entity

  Directly controlled by ASCO

• ASCO ASSOCIATION

  501(C)(6) · PROMOTING COMMON INTERESTS OF MEMBERS · VA · controlled entity

  Directly controlled by ASCO

• ASCO ASSOCIATION POLITICAL ACTION COMM

  527 · ADVOCACY · VA

  Directly controlled by ASCO ASSOC

Taxable family on this return

Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.

Provenance

Return type

form_990

Tax year

2024

Filed

7 November 2025

IRS schema version

2024v5.2

Source object

202513159349304321

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.